Actively Recruiting
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Led by University of Michigan Rogel Cancer Center · Updated on 2025-07-31
60
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
U
University of Michigan Rogel Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
CONDITIONS
Official Title
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male
- 18 years of age or older
- Scheduled for 177Lu-617 PSMA treatment for metastatic castration-resistant prostate carcinoma
- Clinically stable as determined by nuclear medicine clinicians
- Willing and able to provide informed consent
You will not qualify if you...
- Unable to lie flat on the imaging systems long enough to complete imaging protocols
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here